Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer

NCT ID: NCT00915018

Last Updated: 2018-08-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

479 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-08-21

Study Completion Date

2018-06-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is investigating the effects of an experimental drug (neratinib) in combination with paclitaxel versus trastuzumab in combination with paclitaxel for the treatment of women who have not received previous treatment for erbB-2-positive locally recurrent or metastatic breast cancer. The study will compare the effectiveness of each regimen in shrinking tumors and extending the lives of women with erbB-2 (HER2) positive breast cancer. The study will also compare the safety of the two regimens and as well as the quality of life of subjects receiving either regimen.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

neratinib plus paclitaxel

Group Type EXPERIMENTAL

Neratinib

Intervention Type DRUG

Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.

Paclitaxel

Intervention Type DRUG

Paclitaxel - 80 mg/m² IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.

trastuzumab plus paclitaxel

Group Type ACTIVE_COMPARATOR

Trastuzumab

Intervention Type DRUG

Trastuzumab - 4 mg/kg IV initial loading dose followed by subsequent once weekly doses of 2mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.

Paclitaxel

Intervention Type DRUG

Paclitaxel - 80 mg/m² IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neratinib

Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.

Intervention Type DRUG

Trastuzumab

Trastuzumab - 4 mg/kg IV initial loading dose followed by subsequent once weekly doses of 2mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.

Intervention Type DRUG

Paclitaxel

Paclitaxel - 80 mg/m² IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Herceptin Herclon Taxol Abraxane Onxol Nov-onxol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ErbB-2 positive locally recurrent or metastatic breast cancer
* Eastern Cooperative Oncology Group (ECOG) 0-2
* Measurable disease
* Availability of tumor tissue for HER2 status confirmation

Exclusion Criteria

* Prior systemic anti-cancer therapy other than endocrine therapy for locally recurrent or metastatic disease
* Prior erbB-2 inhibitor other than trastuzumab or lapatinib in the neoadjuvant or adjuvant setting
* Progression/recurrence within 12 months after completion of adjuvant or neoadjuvant therapy
* History of heart disease
* History of gastrointestinal disease
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Puma Biotechnology, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Puma

Role: STUDY_DIRECTOR

Biotechnology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ventura County Hematology-Oncology Specialists

Oxnard, California, United States

Site Status

Redwood Regional Medical Group

Santa Rosa, California, United States

Site Status

Cancer Center of Central Connecticut

Plainville, Connecticut, United States

Site Status

Palm Beach Institute of Hematology and Oncology

Boynton Beach, Florida, United States

Site Status

North Broward Medical Center Cancer Center

Deerfield Beach, Florida, United States

Site Status

Broward General Medical Center

Fort Lauderdale, Florida, United States

Site Status

Mid Florida Cancer Centers

Orange City, Florida, United States

Site Status

Florida Cancer Research Institute

Plantation, Florida, United States

Site Status

Hematology Oncology Associates of Treasure Coast

Port Saint Lucie, Florida, United States

Site Status

Phoebe Cancer Center

Albany, Georgia, United States

Site Status

Dublin Hematology and Oncology Care

Dublin, Georgia, United States

Site Status

Clintell

Skokie, Illinois, United States

Site Status

Presence Hematology and Oncology

Skokie, Illinois, United States

Site Status

Springfield Clinic

Springfield, Illinois, United States

Site Status

CHRISTUS St. Frances Cabrini Hospital

Alexandria, Louisiana, United States

Site Status

Hematology Oncology Services

Metairie, Louisiana, United States

Site Status

Park Nicollet Institute

Saint Louis Park, Minnesota, United States

Site Status

Missouri Cancer Associates

Columbia, Missouri, United States

Site Status

St. John's Medical Research Institute

Springfield, Missouri, United States

Site Status

Washington University School of Medicine Siteman Cancer Center

St Louis, Missouri, United States

Site Status

The Valley Hospital, Luckow Pavilion Office of Oncology Clinical Trials

Paramus, New Jersey, United States

Site Status

Gaston Hematology and Oncology Associates

Gastonia, North Carolina, United States

Site Status

Summa Health System Hospitals

Akron, Ohio, United States

Site Status

Warren Cancer Research Foundation

Tulsa, Oklahoma, United States

Site Status

Samaritan Hematology and Oncology Consultants

Corvallis, Oregon, United States

Site Status

Pawtucket Memorial Hospital

Pawtucket, Rhode Island, United States

Site Status

Medical University of South Carolina Hollings Cancer Center

Charleston, South Carolina, United States

Site Status

Santee Hematology Oncology

Sumter, South Carolina, United States

Site Status

Tenessee Cancer Specialists

Knoxville, Tennessee, United States

Site Status

Family Cancer Care

Memphis, Tennessee, United States

Site Status

Texas Oncology

Bedford, Texas, United States

Site Status

El Paso Cancer Treatment Center

El Paso, Texas, United States

Site Status

Texas Oncology-Allison Cancer Center

Midland, Texas, United States

Site Status

Southlake Oncology

Southlake, Texas, United States

Site Status

Utah Cancer Specialists

Salt Lake City, Utah, United States

Site Status

Charleston Area Medical Center, Health, Education, and Research Institute

Charleston, West Virginia, United States

Site Status

The Queen Elizabeth Hospital

North Adelaide, South Australia, Australia

Site Status

Royal Melbourne Hospital

Parkville, Victoria, Australia

Site Status

N.N. Aleksandrov National Cancer Center of Belarus

Lyasny, Minsk Oblast, Belarus

Site Status

Institution of Healthcare Grodno Regional Clinical Hospital

Grodno, , Belarus

Site Status

Institution Gomel Regional Clinical Oncology Dispensary

Homyel, , Belarus

Site Status

Healthcare Institution Vitebsk Regional Clinical Oncology Dispensary

Vitebsk, , Belarus

Site Status

Institut Jules Bordet

Brussels, , Belgium

Site Status

District Dispensary for Oncology Diseases Internal Unit- Plovdiv EOOD

Plovdiv, , Bulgaria

Site Status

District Dispensary for Oncology Diseases Internal Unit- Sofia EOOD

Sofia, , Bulgaria

Site Status

Specialised Hospital of ActiveTreatment in Oncology, Clinic of Chemotherapy

Sofia, , Bulgaria

Site Status

Hopital Charles, LeMoyne Le Centre Intégré de Cancérologie de la Montérégie

Greenfield Park, Quebec, Canada

Site Status

Centre Hospitalier Régional de Trois-Rivières

Trois-Rivières, Quebec, Canada

Site Status

Sun Yat-Sen University Cancer Center

Guangzhou, Guangdong, China

Site Status

Southern Medical University Nanfang Hospital

Guangzhou, Guangdong, China

Site Status

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

Site Status

Cancer Hospital, Chinese Academy of Medical Sciences

Beijing, , China

Site Status

Peking Union Medical College Hospital of Chinese Academy of Medical Sciences

Beijing, , China

Site Status

The Hospital Affiliated Academy Military Medical Science, Chinese People's Liberation Army

Beijing, , China

Site Status

Chinese People's Liberation Army General Hospital

Beijing, , China

Site Status

Fudan University Shanghai Cancer Center

Shanghai, , China

Site Status

Tianjin Cancer Hospital

Tianjin, , China

Site Status

Clinical Hospital Osijek, Department of Radiotherapy and Oncology

Osijek, , Croatia

Site Status

University Hospital For Tumors

Zagreb, , Croatia

Site Status

Rigshospitalet, Copenhagen, Onkologisk Klinik

Copenhagen, , Denmark

Site Status

Hôpital Henri-Mondor

Créteil, , France

Site Status

Centre Leon Berard Departement de Cancerologie Medicale

Lyon, , France

Site Status

Centre Val d'Aurelle

Montpellier, , France

Site Status

Hopital Hotel Dieu, Service d'Oncologie Medicale, Bat B2, 5ieme

Paris, , France

Site Status

Hopital La Pitie-Salpetriere

Paris, , France

Site Status

Groupe Hospitalier Paris Saint Joseph, Oncologie medicale

Paris, , France

Site Status

Service d'Oncologie et de Radiotherapie, Polyclinique Francheville

Périgueux, , France

Site Status

Clinique Armoricaine de Radiologie

Saint-Brieuc, , France

Site Status

Centre de Radiothérapie, Clinique Sainte Anne, Service d'Oncologie Libérale

Strasbourg, , France

Site Status

CHU Strasbourg Departement Oncologie & Hematologie Hopital Civil

Strasbourg, , France

Site Status

CHU Bretonneau, Centre Henry Kaplan

Tours, , France

Site Status

Sozialstiftung Bamberg Klinik fuer Haematologie und internistische Onkologie

Bamberg, , Germany

Site Status

Pamela Youde Nethersole Eastern Hospital

Chai Wan, , Hong Kong

Site Status

Queen Mary Hospital

Hong Kong, , Hong Kong

Site Status

UNIMED Medical Institute, Comprehensive Centre for Breast Diseases

Wan Chai, , Hong Kong

Site Status

Semmelweis Egyetem Radiologiai és Onkoterapias Klinika

Budapest, , Hungary

Site Status

Fovarosi Onkormanyzat Szent Imre Korhaz Klinikai Onkologiai Profil

Budapest, , Hungary

Site Status

Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly

Budapest, , Hungary

Site Status

Kaposi Mor Oktato Korhoz Onkologiai Centrum

Kaposvár, , Hungary

Site Status

Bacs-Kiskun Megyei Onkormanyzat Korhaza Onkoradiologiai Kozpont

Kecskemét, , Hungary

Site Status

Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház

Miskolc, , Hungary

Site Status

Szegedi Tudomanyegyetem Onkoterapias Klinika

Szeged, , Hungary

Site Status

Jawaharlal Nehru Cancer Hospital

Bhopal, Madhya Pradesh, India

Site Status

Tata Memorial Centre

Mumbai, Maharashtra, India

Site Status

Central India Cancer Research Institute

Nagpur, Maharashtra, India

Site Status

Curie Manavata Cancer Centre

Nashik, Maharashtra, India

Site Status

Shatabdi Super Speciality Hospital

Nashilk, Maharashtra, India

Site Status

Deenanath Mangeshkar Hospital and Research Centre

Pune, Maharashtra, India

Site Status

Institute Rotary Cancer Hospital, AIIMS

New Delhi, National Capital Territory of Delhi, India

Site Status

Searoc Cancer Center

Jaipur, Rajasthan, India

Site Status

Meenakshi Mission Hospital and Research Centre

Madurai, Tamil Nadu, India

Site Status

B P Poddar and Medical Research Ltd.

Kolkata, West Bengal, India

Site Status

Kaplan Medical Center

Rehovot, , Israel

Site Status

Sourasky Medical Center

Tel Aviv, , Israel

Site Status

Assaf Harofeh Medical Center

Ẕerifin, , Israel

Site Status

Policlinico di Modena Oncologia ed Ematologia

Modena, , Italy

Site Status

Fondazione Salvatore Maugeri

Pavia, , Italy

Site Status

Policlinico Universitario Campus Bio-Medico

Roma, , Italy

Site Status

Ospedale San Pietro Fatebenefratelli

Roma, , Italy

Site Status

Ospedale San Giovanni Battista-Molinette

Torino, , Italy

Site Status

Hyogo Cancer Center

Hyōgo, Akashi-shi, Japan

Site Status

National Hospital Organization Beppu Medical Center

Ōita, Beppu-shi, Japan

Site Status

Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital

Tokyo, Bunkyo-ku, Japan

Site Status

Chiba Cancer Center

Chiba, Chiba-shi, Japan

Site Status

National Hospital Organization Kyushu Cancer Center

Fukuoka, Fukuoka-shi, Japan

Site Status

National Hospital Organization Mito Medical Center

Ibaraki, Higashiibaraki-gun, Japan

Site Status

Hiroshima University Hospital

Hiroshima, Hiroshima-shi, Japan

Site Status

Hakuaikai Medical Corporation Sagara Hospital

Kagoshima, Kagoshima-city, Japan

Site Status

National Cancer Center Hospital East

Chiba, Kashiwa-shi, Japan

Site Status

Saitama Cancer Center

Saitama, Kitaadachi-gun, Japan

Site Status

Kumamoto Municipal Hospital

Kumamoto, Kumamoto-city, Japan

Site Status

Kurume Daiichi Social Insurance Hospital

Fukuoka, Kurume-Shi, Japan

Site Status

National Hospital Organization Shikoku Cancer Center

Ehime, Matsuyama-city, Japan

Site Status

Iwate Medical University Hospital

Numakunai, Morioka-shi, Japan

Site Status

Aichi Cancer Center

Aichi, Nagoya-shi, Japan

Site Status

National Hospital Organization Nagoya Medical Center

Aichi, Nagoya, Japan

Site Status

Niigata Cancer Center Hospital

Niigata, Niigata-shi, Japan

Site Status

Osaka Medical Center for Cancer and Cardiovascular Diseases

Osaka, Osaka-shi, Japan

Site Status

National Hospital Organization Osaka National Hospital

Osaka, Osaka-shi, Japan

Site Status

National Hospital Organization Hokkaido Cancer Center

Hokkaido, Sapporo-shi, Japan

Site Status

Tohoku University Hospital

Miyagi, Sendai-city, Japan

Site Status

Tenri Hospital

Nara, Tenri-shi, Japan

Site Status

Kanagawa Cancer Center

Kanagawa, Yokohama-City, Japan

Site Status

Hiroshima City Hospital

Hiroshima, , Japan

Site Status

National Hospital Organization Kure Medical Center and Chugoku Cancer Center

Hiroshima, , Japan

Site Status

Kobe City Medical Center General Hospital

Hyōgo, , Japan

Site Status

Shinko Hospital

Hyōgo, , Japan

Site Status

Kumamoto University Hospital

Kumamoto, , Japan

Site Status

Tazuke Kofukai Medical Research Institute Kitano Hospital

Osaka, , Japan

Site Status

Osaka University Hospital

Osaka, , Japan

Site Status

Jichi Medical University Hospital

Tochigi, , Japan

Site Status

Toranomon Hospital

Tokyo, , Japan

Site Status

National Hospital Organization Tokyo Medical Center

Tokyo, , Japan

Site Status

Piejuras Hospital, Liepajas Oncological Clinic

Liepāja, , Latvia

Site Status

Pauls Stradiņš Clinical University Hospital

Riga, , Latvia

Site Status

Riga Eastern University Hospital

Riga, , Latvia

Site Status

Hospital of Lithuanian University of Health sciences

Kaunas, , Lithuania

Site Status

Nacionalinis Vezio Institutas, Vilniaus Universiteto Onkologijos Institutas

Vilnius, , Lithuania

Site Status

University Malaya Medical Centre

Kuala Lumpur, , Malaysia

Site Status

Sir Anthony Oncology Center

Floriana, , Malta

Site Status

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Wojewodzki Oddzial

Jelenia Góra, Lower Silesian Voivodeship, Poland

Site Status

Magodent

Warsaw, Masovian Voivodeship, Poland

Site Status

Opolskie Centrum Onkologii

Opole, Opole Voivodeship, Poland

Site Status

Zakład Opieki Zdrowotnej MSW z Warmińsko, Mazurskim Centrum Onkologii

Olsztyn, Warmian-Masurian Voivodeship, Poland

Site Status

Białostockie Centrum Onkologii

Bialystok, , Poland

Site Status

Hospital da Luz Servico de Oncologia Medica

Lisbon, , Portugal

Site Status

Institutul Oncologic Prof. Dr. Ion Chiricuţă

Cluj-Napoca, Cluj, Romania

Site Status

SC Oncolab S.R.L.

Craiova, Dolj, Romania

Site Status

Spitalul Universitar de Urgenta Bucuresti

Bucharest, , Romania

Site Status

Institute of Oncology and Radiology of Serbia

Belgrade, , Serbia

Site Status

Clinical centre Nis Clinic of Oncology

Niš, , Serbia

Site Status

National University Hospital, National Cancer Institute

Singapore, , Singapore

Site Status

National Cancer Centre Singapore

Singapore, , Singapore

Site Status

GVI Oncology

Port Elizabeth, Eastern Cape, South Africa

Site Status

The Medical Oncology Centre of Rosebank

Johannesburg, Gauteng, South Africa

Site Status

University of Witwatersrand Oncology, Donald Gordon Medical Centre

Johannesburg, Gauteng, South Africa

Site Status

Sandton Oncology Centre

Johannesburg, Gauteng, South Africa

Site Status

Eastleigh Breast Care Centre

Pretoria, Gauteng, South Africa

Site Status

Westridge Medical Centre

Durban, KwaZulu-Natal, South Africa

Site Status

GVI Oncology

Kraaifontein, Western Cape, South Africa

Site Status

National Cancer Center, Center for Breast Cancer

Goyang-si, Gyeonggi-do, South Korea

Site Status

Samsung Medical Center

Seoul, Korea, South Korea

Site Status

Asan Medical Center

Seoul, Korea, South Korea

Site Status

Korea University Guro Hospital

Seoul, Korea, South Korea

Site Status

Yonsei University Health System Severance Hospital

Seoul, Seoul/Korea, South Korea

Site Status

Hospital Son Llàtzer

Palma, Balearic Islands, Spain

Site Status

Hospital Universitari Arnau de Vilanova

Lleida, Catalonia, Spain

Site Status

Complejo Hospitalario Universitario Santiago de Compostela

Santiago de Compostela, Galicia, Spain

Site Status

Hospital Universitario Fundación Alcorcón

Alcorcón, Madrid, Spain

Site Status

Hospital Puerta De Hierro

Majadahonda, Madrid, Spain

Site Status

Hospital Universitario Infanta Cristina

Parla, Madrid, Spain

Site Status

Hospital Madrid Norte Sanchinarro Centro Integral Oncológico Clara Campal Ensayos Clínicos

PAU de Sanchinarro, Madrid, Spain

Site Status

Hospital Costa del Sol

Marbella, Malaga, Spain

Site Status

Hospital de Cruces

Barakaldo, Vizcaya, Spain

Site Status

Centro Oncologico MD Anderson

Madrid, , Spain

Site Status

Hospital Universitario Ramón y Cajal

Madrid, , Spain

Site Status

Hospital Universitario 12 de Octubre

Madrid, , Spain

Site Status

Tumor Center Hirslanden Medical Center

Aarau, , Switzerland

Site Status

Spital STS AG Onkologiezentrum Thun - Berner Oberland

Thun, , Switzerland

Site Status

Kantonsspital Winterthur Medizinische Onkologie

Winterthur, , Switzerland

Site Status

Chang Gung Medical Foundation, Linkou Branch

Taoyuan District, , Taiwan

Site Status

Affinity Research Limited

Nassau, CB, The Bahamas

Site Status

Ege Universitesi Tip Fakultesi Tulay Aktas Onkoloji Hastanesi

Bornova, İzmir, Turkey (Türkiye)

Site Status

Komunalnyy Zaklad Cherkasskyy Oblasnyy Onkologichnyy Dyspanser

Cherkassy, , Ukraine

Site Status

Chernivtsi Regional Oncology Centre Outpatient Department Bukovynian State Medical University Department of Oncology and Radiology

Chernivtsi, , Ukraine

Site Status

City Multifield Clinical Hospital

Dnipropetrovsk, , Ukraine

Site Status

Donetsk Regional Antitumor Center Department of Pretumor Diseases and Tumor Treatment

Donetsk, , Ukraine

Site Status

S.P. Grigoreva Institute of Medical Radiology Department of Chemotherapy

Kharkiv, , Ukraine

Site Status

National Institute of Cancer Department of Conseravtive Methods of Treatment

Kyiv, , Ukraine

Site Status

Volyn Regional Oncological Center

Lutsk, , Ukraine

Site Status

State Oncological Regional Treatment and Diagnostic Center

Lviv, , Ukraine

Site Status

Mariupil Oncological Center

Mariupil, , Ukraine

Site Status

Sumy Regional Clinical Oncology Centre

Sumy, , Ukraine

Site Status

Guy's and St Thomas NHS Foundation Trust Management Offices 4th Floor Bermondsey Wing Guy's Hospital

London, , United Kingdom

Site Status

Nottingham University Hospital

Nottingham, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Belarus Belgium Bulgaria Canada China Croatia Denmark France Germany Hong Kong Hungary India Israel Italy Japan Latvia Lithuania Malaysia Malta Poland Portugal Romania Serbia Singapore South Africa South Korea Spain Switzerland Taiwan The Bahamas Turkey (Türkiye) Ukraine United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T, Goswami C, Deo S, Bose R, Wong A, Xu F, Yao B, Bryce R, Carey LA. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial. JAMA Oncol. 2016 Dec 1;2(12):1557-1564. doi: 10.1001/jamaoncol.2016.0237.

Reference Type DERIVED
PMID: 27078022 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3144A2-3005 / B1891005

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
NCT05458674 RECRUITING PHASE2